{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:19:36Z","timestamp":1789827576936,"version":"4.0.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.suronc.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T12:03:34Z","timestamp":1549281814000},"page":"214-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Osteonecrosis in pediatric cancer survivors: Epidemiology, risk factors, and treatment"],"prefix":"10.1016","volume":"28","author":[{"given":"Sandesh S.","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad M.","family":"El Abiad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Puvanesarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol D.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib1","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/1097-0142(197511)36:5<1585::AID-CNCR2820360508>3.0.CO;2-D","article-title":"Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids)","volume":"36","author":"Ihde","year":"1975","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2214\/AJR.10.6073","article-title":"Osteonecrosis in children after therapy for malignancy","volume":"196","author":"Kaste","year":"2011","journal-title":"AJR Am. J. Roentgenol."},{"issue":"12","key":"10.1016\/j.suronc.2019.02.001_bib3","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/1097-0142(19810615)47:12<2793::AID-CNCR2820471206>3.0.CO;2-A","article-title":"Avascular necrosis of bone in Hodgkin's disease patients treated with combined modality therapy","volume":"47","author":"Prosnitz","year":"1981","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-85-1-67","article-title":"Avascular necrosis of the femoral head with combination therapy","volume":"85","author":"Sweet","year":"1976","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12178-015-9277-8","article-title":"Pathophysiology and risk factors for osteonecrosis","volume":"8","author":"Shah","year":"2015","journal-title":"Curr Rev Musculoskelet Med"},{"issue":"8","key":"10.1016\/j.suronc.2019.02.001_bib6","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2010-10-311969","article-title":"Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia","volume":"117","author":"Kawedia","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00043426-198821000-00009","article-title":"Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P","volume":"10","author":"Gaynon","year":"1988","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00043426-199502000-00001","article-title":"The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations","volume":"17","author":"Gaynon","year":"1995","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.suronc.2019.02.001_bib9","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1200\/JCO.1993.11.11.2234","article-title":"Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106","volume":"11","author":"Gaynon","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2019.02.001_bib10","first-page":"87","article-title":"Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a Report from the BFM study group","volume":"26","author":"Henze","year":"1981","journal-title":"Haematol. Blood Transfus."},{"issue":"18","key":"10.1016\/j.suronc.2019.02.001_bib11","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2000.18.18.3262","article-title":"Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the children's cancer group","volume":"18","author":"Mattano","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.suronc.2019.02.001_bib12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/oxfordjournals.annonc.a057856","article-title":"Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: the Berlin-Frankfurt-Munster and Dana-Farber Cancer Institute protocols","volume":"2","author":"Niemeyer","year":"1991","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.suronc.2019.02.001_bib13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/mpo.2950210909","article-title":"Avascular femoral head necrosis in pediatric cancer patients","volume":"21","author":"Hanif","year":"1993","journal-title":"Med. Pediatr. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF00445806","article-title":"Avascular necrosis of bone in neuroblastoma treated with combination chemotherapy","volume":"143","author":"Ishii","year":"1984","journal-title":"Eur. J. Pediatr."},{"issue":"18","key":"10.1016\/j.suronc.2019.02.001_bib15","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2007.14.9088","article-title":"Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study","volume":"26","author":"Kadan-Lottick","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mph.0000163215.37147.13","article-title":"Aseptic osteonecrosis in children and adolescents treated for hemato-oncologic diseases: a 13-year longitudinal observational study","volume":"27","author":"Lackner","year":"2005","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib17","first-page":"689","article-title":"The clavicle: a vulnerable bone in pediatric oncology","volume":"18","author":"Zietz","year":"2001","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib18","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/cam4.645","article-title":"Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL)","volume":"5","author":"Padhye","year":"2016","journal-title":"Cancer Med"},{"issue":"31","key":"10.1016\/j.suronc.2019.02.001_bib19","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2011.37.3217","article-title":"Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia","volume":"29","author":"te Winkel","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3324\/haematol.2013.095562","article-title":"Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia","volume":"99","author":"te Winkel","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib21","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1200\/JCO.2012.43.6733","article-title":"Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors","volume":"31","author":"Fangusaro","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.arbres.2012.01.007","article-title":"Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab","volume":"48","author":"Katsenos","year":"2012","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.suronc.2019.02.001_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1302\/0301-620X.67B1.3155745","article-title":"Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment","volume":"67","author":"Ficat","year":"1985","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.suronc.2019.02.001_bib24","series-title":"Osteonecrosis","first-page":"201","article-title":"The University of Pennsylvania classification of osteonecrosis","author":"Steinberg","year":"2014"},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib25","first-page":"41","article-title":"A new international classification of osteonecrosis of the ARCO committee on terminology and classification","volume":"4","author":"Gardeniers","year":"1992","journal-title":"ARC News"},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s007760200108","article-title":"The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head","volume":"7","author":"Sugano","year":"2002","journal-title":"J. Orthop. Sci."},{"issue":"8","key":"10.1016\/j.suronc.2019.02.001_bib27","first-page":"1096","article-title":"Osteonecrosis after allogeneic stem cell transplantation in childhood. A case-control study in Italy","volume":"91","author":"Faraci","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.bmt.1704360","article-title":"Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation","volume":"33","author":"Kaste","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/bmt.2010.210","article-title":"Prevalence of osteonecrosis and associated risk factors in children before allogeneic BMT","volume":"46","author":"Sharma","year":"2011","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2015-10-673848","article-title":"Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia","volume":"127","author":"Karol","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib31","doi-asserted-by":"crossref","first-page":"L740","DOI":"10.1152\/ajplung.00284.2002","article-title":"Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells","volume":"285","author":"Zhang","year":"2003","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"23","key":"10.1016\/j.suronc.2019.02.001_bib32","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1101\/gad.1727208","article-title":"Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity","volume":"22","author":"Johnson","year":"2008","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.atherosclerosis.2009.02.026","article-title":"Prox-1 and FOXC2 gene expression in adipose tissue: a potential contributory role of the lymphatic system to familial combined hyperlipidaemia","volume":"206","author":"Horra","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00043426-199505000-00008","article-title":"Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies","volume":"17","author":"Alvarez","year":"1995","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.suronc.2019.02.001_bib35","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archinte.1983.00350070063012","article-title":"Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy","volume":"143","author":"Cassileth","year":"1983","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/ecp.11.1","article-title":"Corticosteroids in brain cancer patients: benefits and pitfalls","volume":"4","author":"Dietrich","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.cdd.4400969","article-title":"Recent insights into the mechanism of glucocorticosteroid-induced apoptosis","volume":"9","author":"Distelhorst","year":"2002","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib38","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-84-3-304","article-title":"Glucocorticosteroid therapy: mechanisms of action and clinical considerations","volume":"84","author":"Fauci","year":"1976","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"10.1016\/j.suronc.2019.02.001_bib39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","article-title":"Glucocorticoid use in acute lymphoblastic leukaemia","volume":"11","author":"Inaba","year":"2010","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib40","first-page":"353","article-title":"The relationship between blood flow and marrow cavity pressure of bone","volume":"135","author":"Shim","year":"1972","journal-title":"Surg. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00005792-198003000-00004","article-title":"Ischemic bone necrosis in systemic lupus erythematosus. II. The early diagnosis of ischemic necrosis of bone","volume":"59","author":"Zizic","year":"1980","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib42","first-page":"252","article-title":"Histologic demonstration of fat emboli in aseptic necrosis associated with hypercortisonism","volume":"44","author":"Fisher","year":"1969","journal-title":"Mayo Clin. Proc."},{"issue":"3\u20135","key":"10.1016\/j.suronc.2019.02.001_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jsbmb.2009.02.007","article-title":"Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action","volume":"114","author":"Kerachian","year":"2009","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib44","article-title":"Asparaginase potentiates glucocorticoid-induced osteonecrosis in a mouse model","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.suronc.2019.02.001_bib45","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1002\/art.20517","article-title":"Combined effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits","volume":"50","author":"Motomura","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"2\u20134","key":"10.1016\/j.suronc.2019.02.001_bib46","first-page":"221","article-title":"Role of apoptosis in glucocorticoid-induced osteoporosis and osteonecrosis","volume":"13","author":"Zalavras","year":"2003","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"issue":"20","key":"10.1016\/j.suronc.2019.02.001_bib47","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children's oncology group study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.suronc.2019.02.001_bib48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.8.8","article-title":"Dexamethasone(DEX)(6mg\/sm\/d) and prednisolone(PRED)(60mg\/sm\/d) in induction therapy of childhood all are equally effective: results of the 2nd interim analysis of EORTC trial 58951","volume":"112","author":"Bertrand","year":"2008","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.suronc.2019.02.001_bib49","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1200\/JCO.2005.01.982","article-title":"No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol","volume":"23","author":"Igarashi","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.suronc.2019.02.001_bib50","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"Moricke","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.suronc.2019.02.001_bib51","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.suronc.2019.02.001_bib52","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1200\/JCO.2001.19.12.3066","article-title":"Bony morbidity in children treated for acute lymphoblastic leukemia","volume":"19","author":"Strauss","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.suronc.2019.02.001_bib53","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1470-2045(12)70274-7","article-title":"Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial","volume":"13","author":"Mattano","year":"2012","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.suronc.2019.02.001_bib54","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/MPH.0b013e31818ab29d","article-title":"Osteonecrosis in children treated for lymphoma or solid tumors","volume":"30","author":"Niinimaki","year":"2008","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mpo.1366","article-title":"Aseptic osteonecrosis in a child with nephroblastoma healed by hyperbaric oxygen therapy","volume":"39","author":"Bernbeck","year":"2002","journal-title":"Med. Pediatr. Oncol."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3928\/01477447-20100429-22","article-title":"Complications associated with treatment of malignancies: a focus on avascular necrosis of the bone","volume":"33","author":"Newland","year":"2010","journal-title":"Orthopedics"},{"issue":"17","key":"10.1016\/j.suronc.2019.02.001_bib57","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.2217\/fon.15.114","article-title":"L-asparaginase and venous thromboembolism in acute lymphocytic leukemia","volume":"11","author":"Goyal","year":"2015","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib58","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01958270","article-title":"Osteonecrosis of vertebrae in a child with acute lymphocytic leukaemia during L-asparaginase therapy","volume":"149","author":"Hanada","year":"1989","journal-title":"Eur. J. Pediatr."},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib59","first-page":"220","article-title":"L-asparaginase for the treatment of cancer","volume":"23","author":"McCredie","year":"1973","journal-title":"Ca - Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib60","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood.V89.6.1886","article-title":"Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"89","author":"Parsons","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.suronc.2019.02.001_bib61","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1200\/JCO.2007.13.8404","article-title":"Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia","volume":"26","author":"Yang","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/mpo.2950070408","article-title":"L-asparaginase effect on antithrombin-III levels","volume":"7","author":"Anderson","year":"1979","journal-title":"Med. Pediatr. Oncol."},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib63","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1200\/JCO.1987.5.5.811","article-title":"Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia","volume":"5","author":"Homans","year":"1987","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib64","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0022-3476(82)80536-2","article-title":"The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia","volume":"100","author":"Ramsay","year":"1982","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib65","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2012.290","article-title":"The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia","volume":"27","author":"Truelove","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib66","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0049-3848(90)90122-S","article-title":"L-asparaginase treatment reduces the anticoagulant potential of the protein C system without affecting vitamin K-dependent carboxylation","volume":"59","author":"Vigano'D'Angelo","year":"1990","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib67","first-page":"194","article-title":"L-Asparginase induced cortical venous thrombosis in a patient with acute leukemia","volume":"3","author":"Dubashi","year":"2012","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/1817-1745.66683","article-title":"Sagittal sinus thrombosis due to L-asparaginase","volume":"5","author":"Wani","year":"2010","journal-title":"J. Pediatr. Neurosci."},{"key":"10.1016\/j.suronc.2019.02.001_bib69","series-title":"Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring","first-page":"135","article-title":"Drug metabolism, transport and influence of hepatic disease","author":"Kashuba","year":"2006"},{"issue":"7","key":"10.1016\/j.suronc.2019.02.001_bib70","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2011-09-381731","article-title":"Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia","volume":"119","author":"Kawedia","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib72","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib73","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/pbc.21559","article-title":"Avascular necrosis of femoral head in childhood acute myeloid leukemia: complication of chemotherapy without steroids","volume":"51","author":"Ghosh","year":"2008","journal-title":"Pediatr. Blood Canc."},{"issue":"6413","key":"10.1016\/j.suronc.2019.02.001_bib74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/bmj.288.6413.267","article-title":"Avascular necrosis of bone caused by combination chemotherapy without corticosteroids","volume":"288","author":"Harper","year":"1984","journal-title":"Br. Med. J."},{"issue":"9","key":"10.1016\/j.suronc.2019.02.001_bib75","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2217\/fon.14.62","article-title":"Immunotherapy in pediatric malignancies: current status and future perspectives","volume":"10","author":"Capitini","year":"2014","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib76","doi-asserted-by":"crossref","first-page":"506","DOI":"10.14219\/jada.archive.2011.0220","article-title":"Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab","volume":"142","author":"Francini","year":"2011","journal-title":"J. Am. Dent. Assoc."},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib77","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib78","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","article-title":"Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor","volume":"288","author":"Lin","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"24","key":"10.1016\/j.suronc.2019.02.001_bib79","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.suronc.2019.02.001_bib80","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc905","article-title":"Clinical translation of angiogenesis inhibitors","volume":"2","author":"Kerbel","year":"2002","journal-title":"Nat. Rev. Canc."},{"issue":"25","key":"10.1016\/j.suronc.2019.02.001_bib81","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib82","first-page":"9313","article-title":"The association between VEGF -634C\/G polymorphisms and osteonecrosis of femoral head: a meta-analysis","volume":"8","author":"Wang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib83","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/1078-0432.CCR-12-1897","article-title":"Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory\/recurrent solid tumors","volume":"19","author":"Navid","year":"2013","journal-title":"Clin. Canc. Res."},{"issue":"9","key":"10.1016\/j.suronc.2019.02.001_bib84","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/pbc.24547","article-title":"Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors","volume":"60","author":"Wagner","year":"2013","journal-title":"Pediatr. Blood Canc."},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semradonc.2009.09.001","article-title":"Radiation-related treatment effects across the age spectrum: differences and similarities or what the old and young can learn from each other","volume":"20","author":"Krasin","year":"2010","journal-title":"Semin. Radiat. Oncol."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib86","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1302\/0301-620X.77B6.7593093","article-title":"Total hip replacement in irradiated hips. A retrospective study of 71 cases","volume":"77","author":"Massin","year":"1995","journal-title":"J Bone Joint Surg Br"},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib87","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.rpor.2011.04.004","article-title":"Radiotherapy induced hip joint avascular necrosis-Two cases report","volume":"16","author":"Michalecki","year":"2011","journal-title":"Rep. Practical Oncol. Radiother."},{"issue":"8","key":"10.1016\/j.suronc.2019.02.001_bib88","first-page":"1089","article-title":"Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies","volume":"18","author":"Peterson","year":"2010","journal-title":"Support. Care Canc."},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib89","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.1015350108","article-title":"Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells","volume":"108","author":"Cao","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib90","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bone.2013.02.023","article-title":"PTH prevents the adverse effects of focal radiation on bone architecture in young rats","volume":"55","author":"Chandra","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.suronc.2019.02.001_bib91","first-page":"323","article-title":"Effects of radiation on bone, cartilage and teeth","volume":"35","author":"Gates","year":"1943","journal-title":"Arch. Pathol."},{"issue":"2","key":"10.1016\/j.suronc.2019.02.001_bib92","first-page":"189","article-title":"Bilateral protusio acetabuli following pelvic irradiation","volume":"4","author":"Hasselbacher","year":"1977","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.suronc.2019.02.001_bib93","first-page":"93","article-title":"Tissue reactions to radiation","volume":"15","author":"Ewing","year":"1926","journal-title":"Am. J. Roentgenol."},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib94","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00256-016-2329-3","article-title":"Lower-limb MRI in the staging and re-staging of osteonecrosis in paediatric patients affected by acute lymphoblastic leukaemia after therapy","volume":"45","author":"Ippolito","year":"2016","journal-title":"Skeletal Radiol."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib95","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2014.57.5480","article-title":"Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids","volume":"33","author":"Kaste","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib96","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.leu.2402139","article-title":"Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma","volume":"15","author":"Ribeiro","year":"2001","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib97","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40291-016-0226-z","article-title":"Genetic biomarkers to identify the risk of osteonecrosis in children with acute lymphoblastic leukemia","volume":"20","author":"den Hoed","year":"2016","journal-title":"Mol. Diagn. Ther."},{"issue":"15","key":"10.1016\/j.suronc.2019.02.001_bib98","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood-2015-05-643601","article-title":"Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia","volume":"126","author":"Karol","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib99","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/MNM.0000000000000284","article-title":"Prediction of femoral head collapse in osteonecrosis using 18F-fluoride positron emission tomography","volume":"36","author":"Kubota","year":"2015","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.suronc.2019.02.001_bib100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00003086-199603000-00020","article-title":"Core decompression versus nonoperative management for osteonecrosis of the hip","volume":"324","author":"Mont","year":"1996","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib101","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2613.2012.00836.x","article-title":"Weight bearing does not contribute to the development of osteonecrosis of the femoral head","volume":"93","author":"Okazaki","year":"2012","journal-title":"Int. J. Exp. Pathol."},{"issue":"8","key":"10.1016\/j.suronc.2019.02.001_bib102","first-page":"3433","article-title":"Efficiency of iloprost treatment for chemotherapy-associated osteonecrosis after childhood cancer","volume":"29","author":"Jager","year":"2009","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib103","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jbspin.2007.12.008","article-title":"Lovastatin inhibits adipogenesis and prevents osteonecrosis in steroid-treated rabbits","volume":"75","author":"Pengde","year":"2008","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib104","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/archdischild-2015-309934","article-title":"QUESTION 1: should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?","volume":"101","author":"Amin","year":"2016","journal-title":"Arch. Dis. Child."},{"issue":"7","key":"10.1016\/j.suronc.2019.02.001_bib105","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/pbc.22428","article-title":"Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL)","volume":"54","author":"Kotecha","year":"2010","journal-title":"Pediatr. Blood Canc."},{"issue":"6","key":"10.1016\/j.suronc.2019.02.001_bib106","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-2004-832341","volume":"216","author":"Bernbeck","year":"2004","journal-title":"Klin. P\u00e4diatr."},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib107","doi-asserted-by":"crossref","first-page":"435","DOI":"10.5604\/15093492.1005091","article-title":"The effects of treatment the avascular necrosis of the femoral head with extracorporeal focused shockwave therapy","volume":"14","author":"Kusz","year":"2012","journal-title":"Ortop. Traumatol. Rehabil."},{"key":"10.1016\/j.suronc.2019.02.001_bib108","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12891-015-0837-2","article-title":"Extracorporeal shock wave therapy in the treatment of primary bone marrow edema syndrome of the knee: a prospective randomised controlled study","volume":"16","author":"Gao","year":"2015","journal-title":"BMC Muscoskelet. Disord."},{"issue":"Pt B","key":"10.1016\/j.suronc.2019.02.001_bib109","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijsu.2015.06.080","article-title":"Extracorporeal shockwave therapy for avascular necrosis of femoral head","volume":"24","author":"Wang","year":"2015","journal-title":"Int. J. Surg."},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/rheumatology\/ken020","article-title":"Extracorporeal shockwave therapy shows regeneration in hip necrosis","volume":"47","author":"Wang","year":"2008","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091581","article-title":"A novel single pulsed electromagnetic field stimulates osteogenesis of bone marrow mesenchymal stem cells and bone repair","volume":"9","author":"Fu","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib112","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2106\/00004623-199503000-00018","article-title":"Non-traumatic avascular necrosis of the femoral head","volume":"77","author":"Mont","year":"1995","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib113","first-page":"6162","article-title":"Core decompression and autologous bone marrow concentrate for treatment of femoral head osteonecrosis: a randomized prospective study","volume":"8","author":"Pepke","year":"2016","journal-title":"Orthop. Rev."},{"issue":"5","key":"10.1016\/j.suronc.2019.02.001_bib114","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.arth.2011.08.008","article-title":"Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study","volume":"27","author":"Sen","year":"2012","journal-title":"J. Arthroplasty"},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4055\/cios.2016.8.1.1","article-title":"Stem cell therapy for the treatment of hip osteonecrosis: a 30-year review of progress","volume":"8","author":"Hernigou","year":"2016","journal-title":"Clin. Orthop. Surg."},{"issue":"1","key":"10.1016\/j.suronc.2019.02.001_bib116","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bone.2011.11.002","article-title":"Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells","volume":"50","author":"Zhao","year":"2012","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.suronc.2019.02.001_bib117","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1302\/0301-620X.87B7.16289","article-title":"The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone","volume":"87","author":"Hernigou","year":"2005","journal-title":"J Bone Joint Surg Br"},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib118","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/BPO.0b013e3181a5ec1f","article-title":"Thorough debridement under endoscopic visualization with bone grafting and stabilization for femoral head osteonecrosis in children","volume":"29","author":"Wells","year":"2009","journal-title":"J. Pediatr. Orthop."},{"issue":"3","key":"10.1016\/j.suronc.2019.02.001_bib119","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.knee.2009.09.004","article-title":"Matrix-assisted autologous chondrocyte implantation into a 14cm(2) cartilage defect, caused by steroid-induced osteonecrosis","volume":"17","author":"Clar","year":"2010","journal-title":"Knee"},{"issue":"12","key":"10.1016\/j.suronc.2019.02.001_bib120","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1007\/s11999-008-0352-y","article-title":"Femoral resurfacing in young patients with hematologic cancer and osteonecrosis","volume":"466","author":"Karimova","year":"2008","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"4","key":"10.1016\/j.suronc.2019.02.001_bib121","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/jayao.2013.0006","article-title":"Incidence of severe osteonecrosis requiring total joint arthroplasty in children and young adults treated for leukemia or lymphoma: a nationwide, register-based study in Finland and Denmark","volume":"2","author":"Niinimaki","year":"2013","journal-title":"J. Adolesc. Young Adult Oncol."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740418303244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740418303244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:17:04Z","timestamp":1760757424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740418303244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":121,"alternative-id":["S0960740418303244"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2019.02.001","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteonecrosis in pediatric cancer survivors: Epidemiology, risk factors, and treatment","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}